Colin Hill has a range of work experience in various roles and industries. Colin started their career as an Engineering Co-op at The Dow Chemical Company in 1993. Later, in 1996, they interned at the Santa Fe Institute. In 2000, they became the Chairman of Gene Network Sciences Inc. In 2008, they took on the role of Chairman at Fina Technologies until 2012. In 2010, they became the CEO of Aitia. Additionally, they served as a Member of the Board of Directors at BioTelemetry Healthcare and PPD, starting in 2016 and 2017 respectively.
Colin Hill pursued a Bachelor of Science degree in Physics from Virginia Tech, starting in 1991 and completing in 1996. Colin then went on to Cornell University, where they obtained a Master's degree in Physics from 1997 to 2000. There is no available information about Colin Hill's education history at McGill University.
Org chart
Teams
Offices
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.
